Metrics cut 3
- Generic Advair opportunity: no longer a US$100M+ opportunity due to 3–4 competitors (prior view was $100M+)
- Lanreotide (Pharmathene): excluded from Q4 FY27 projections; timeline fluid pending FDA remediation/tech transfer
- South Africa reported revenue: continued lost-tender impact expected in coming quarters, limiting reported revenue recovery
Event Participants
Executives
3 Achin Gupta, Ashish Adukia, Diksha Maheshwari
Analysts
11 Abdulkader Puranwala, Bino Pathiparampil, Damayanti Kerai, Foram Parekh, Maulik (360 ONE Capital), Saion Mukharji, Shashank Krishnakumar, Shyam Srinivasan, Tushar Manudhane, Vishal Manchanda, Vivek Agrawal
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Revenue | ₹7,119 crores | Highest-ever Q1; +2% YoY reported; ~+4% adjusted for reclassification of certain marketing/promotional expenses as revenue reduction effective April 1, 2026 (largely impacting South Africa). |
| EBITDA margin | 16.7% | Excluding other income; impacted by product mix, war-related costs (~1–2% of revenue), higher-than-normal inventory write-offs, and phasing of incentives; FY27 guidance maintained at 18.5–20%. |
| Gross margin | 62.5% | After material cost; incorporates product mix, war-related costs, inventory-related charges, and incentive phasing; mix expected to improve from Q3 with winter-season products and new launches. |
| R&D expenditure | ₹486 crores (6.8% of revenue) | Directed largely towards product filings and key development programmes; investments slightly increased. |
| Profit after tax | ₹789 crores (11% of sales) | Effective tax rate of 27% for the quarter. |
| Net cash position | ₹9,494 crores | After dividend payment of ₹1,050 crores during the quarter; total debt including lease liabilities stood at ₹600 crores. |
Geographic & Segment Commentary
One India: Delivered highest-ever quarterly revenue with 12% YoY growth. Branded prescription business grew 15.4% (IQVIA), with respiratory +15%, anti-diabetes +43%, cardiac +20%, and urology double-digit. Chronic mix strengthened to 60.4%; added 2 brands to ₹100+ crore club (total 33) and holds 23 brands in IPM top 300. Foracort remains the #1 respiratory brand (₹1,000+ crore franchise). Company is the largest pharma by volume in IPM with 2 billion+ unit sales (IQVIA MAT Jun'26). New launches include Duolin Synchrobreathe, Bilafav M, UPADACIP (immunology), Byefilm, and Yurpeak (obesity, via Eli Lilly collaboration). Trade generics saw healthy growth with 3 new launches; Consumer Health (Nicotex, Omnigel, Cipladine) holds #1 positions in respective segments.
North America: Revenue of US$162 million; remains #1 in U.S. Albuterol MDI with 21% market share (IQVIA week ending June 2026). Launched generic Ventolin during the quarter with commercial shipments started; also launched Nintedanib and Dapagliflozin, with Liraglutide recently launched. Pipeline for rest of FY27 includes 4 significant launches — 3 respiratory assets (including generic Advair) and 1 large peptide. Two respiratory filings are from U.S. manufacturing facilities and one from Goa; management expects sequential growth through the year.
South Africa: Private market secondary growth of 6.5% outpaced market growth of 5.7% (IQVIA MAT). Reported revenue was impacted by a lost tender and hedged currency movements; tender impact will continue in coming quarters. OTC/consumer growth was normal after adjusting for the presentation reclassification.
EMEU: Continued growth trajectory with +5% YoY in USD terms, driven by both DTM and B2B segments. Margin stability was maintained while leveraging internal pipeline assets.
Company-Specific & Strategic Commentary
U.S. Launch Pipeline & $1B Exit Run Rate: Four significant launches (3 respiratory including generic Advair, 1 large peptide) plus Ventolin scale-up are expected to drive a ~US$1 billion annualized exit run rate by Q4 FY27. Generic Ventolin has six-month CGT exclusivity; peptide launch is a function of complexity and approval, not litigation. Advair is no longer a $100M+ opportunity due to 3–4 competitors.
India Portfolio & Chronic Expansion: Strategy targets respiratory (one-third of business), diabetes, cardiology, urology, and dermatology to increase chronic share; diabetes presence has expanded from rank 30+ four years ago to a full portfolio including GLP-1, insulin, and inhaled insulin. Field force stands at ~12,000 with no significant additions planned; productivity initiatives are the focus.
Accounting Reclassification: Effective April 1, 2026, certain marketing and promotional expenditures are presented as a reduction from revenue instead of operating expenditure; reported revenue growth was 2% YoY vs ~4% adjusted. The change primarily impacts South Africa.
Capital Allocation & Leadership: Priorities remain increased organic capex, R&D/biosimilars, in-licensing, and differentiated M&A in the U.S. and Europe, with a conservative approach to larger deals. Ashish Adukia transitions out and Dinesh Jain (30+ years at Cipla) takes over as Global CFO.
Regulatory & Facilities: U.S. FDA completed routine GMP inspection and PAI at Verna, Goa — classified VAI. Invagen (New York) routine inspection concluded with one Form 483 observation, which management is committed to addressing; Indore facility reinspection is expected anytime.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| EBITDA margin (FY27) | 18.5%–20% (unchanged) | Predicated on successful new U.S. product launches, margin improvement, and cost optimization; risk exists if launch timing slips. |
| North America revenue exit run rate (Q4 FY27) | ~US$1 billion annualized | Based on Ventolin scale-up, 3 respiratory launches (incl. generic Advair), 1 large peptide, plus smaller launches; assumes current competitive landscape. |
| Ventolin ramp-up | End of FY27 | Commercial shipments commenced; volumes expected to increase as supply scales up through the year. |
| South Africa reported revenue | Continued tender impact over coming quarters | Lost tender affects supply plan this year; private market growth (6.5% secondary) expected to continue outpacing market. |
| Indore facility | Reinspection expected anytime | Outcome could affect future filings/supply; timing pending regulatory schedule. |
| Lanreotide (Pharmathene) | Not included in Q4 FY27 projections | Two-pronged approach: FDA remediation for resumption and tech transfer to an alternative U.S. site; timing fluid pending regulatory approvals. |
Risks & Constraints
| Risk | Context |
|---|---|
| U.S. launch timeline delays | EBITDA margin guidance and $1B exit rate depend on timely approvals of Advair, peptide, and other respiratory assets; management explicitly noted plan changes create risk to margin guidance. |
| Competitive intensity in Advair | With 3–4 competitors already in generic Advair, it is not a $100M+ opportunity; overall U.S. growth relies on first-mover advantage in Ventolin (6-month exclusivity), the peptide, and other complex products. |
| War-related cost inflation | Estimated ~1–2% of revenue impact; duration is uncertain and continues to pressure gross margins in FY27. |
| South Africa tender loss | Lost tender continues to weigh on reported revenue in coming quarters; management bids tenders only if margin-accretive, limiting near-term recovery. |
| Regulatory outcomes | Invagen NY received one Form 483 observation; Indore reinspection pending. Adverse findings could delay some smaller products, though major respiratory launches have already been inspected at their respective facilities. |
| Inventory write-offs | Higher-than-normal inventory charges due to expiry, demand shortfalls, or quality issues remained in COGS; could cause quarterly gross margin volatility. |
| Currency impact in South Africa | Favorable ZAR movement was hedged, but reported revenue still reflects currency and tender effects, making private-market growth less visible in reported numbers. |
Q&A Highlights
Accounting Change and India Growth Decomposition
- Question: How has the accounting change impacted growth rates, and can you provide adjusted numbers for India and South Africa? Excluding Yurpeak, Pfizer distribution, and small acquisitions, what is India's organic growth? (Saion Mukharji, Nomura)
- Answer: Reported growth was 2%, but adjusted growth is
4% after normalizing prior-year numbers; the change is largely in South Africa. For India, IQVIA Rx growth was 15.4%, with Yurpeak contributing ~₹80 crores (1.5%); in-licensed products form 10–15% of total business and the remaining base is delivering healthy double-digit growth. (Ashish Adukia, Achin Gupta)
U.S. Launch Pipeline and $1 Billion Exit Run Rate
- Question: You previously mentioned four peptide products; has that changed? Is the $1 billion exit run rate for FY27 still maintained? (Damayanti Kerai, HSBC)
- Answer: The pipeline is 3 significant respiratory launches plus 1 large peptide, in addition to Ventolin and other already-launched products like Liraglutide. Approvals of these will provide line of sight to the $1B exit rate; the base is not large enough, so growth must come from these new products. (Achin Gupta)
Advair Opportunity and Competitive Landscape
- Question: Is Advair still a $100 million-plus opportunity? (Abdulkader Puranwala, ICICI Securities)
- Answer: No — generic Advair now has 3–4 competitors, so it won't be $100M. The $1B exit will be driven by the aggregate of Ventolin, 3 respiratory launches, 1 large peptide, and a bunch of smaller launches contributing to the base. (Achin Gupta)
Gross Margin Pressure and Trajectory
- Question: Can you quantify inventory write-offs and the war/inflation impact on gross margins? What is the right FY27 gross margin level? (Vishal Manchanda, Systematix; Vivek Agrawal, Citi)
- Answer: War-related cost impact is roughly 1–2% of revenue and evolving; inventory charges were higher than normalized but not quantified. Product mix remains the main driver — Q3 typically brings a better recipe mix, and new U.S. products carry healthy margins, so 18.5–20% EBITDA guidance is retained. (Ashish Adukia, Achin Gupta)
South Africa Tender Impact
- Question: Is the tender loss a first-quarter event? Will reported revenue decline continue for the rest of the year? (Bino Pathiparampil, Elara Capital)
- Answer: Yes, the lost tender has a supply plan that impacts this year and will continue to affect coming quarters. Management bids tenders only where margin-accretive; private market is growing faster than the market (6.5% vs 5.7%). (Ashish Adukia)
Yurpeak and Anti-Obesity Segment
- Question: How should we read the anti-obesity market given divergent signals and generic semaglutide competition? (Shyam Srinivasan, Goldman Sachs)
- Answer: The strategy is to back the innovator tirzepatide (Yurpeak) — a high-involvement therapy requiring prescriber connect and patient management. Yurpeak is already the #2 brand in the category after Mounjaro and growing month-on-month; generics and branded products can coexist, and Cipla expects continued progressive growth. (Achin Gupta)
Capital Allocation Priorities
- Question: How will you deploy the ~US$1 billion+ net cash pile? (Shyam Srinivasan, Goldman Sachs)
- Answer: Priorities remain increased organic capex, R&D/biosimilars, in-licensing (including upfronts), and differentiated M&A in the U.S. and Europe. The approach is conservative; for larger opportunities, the company would come back to shareholders. (Ashish Adukia)
EBITDA Margin Recovery and Launch-Related Spending
- Question: Margins have fallen below pre-Revlimid levels — is the U.S. business loss-making? When can we reach 22–23% margins? (Vivek Agrawal, Citi; Foram Parekh, BOB Capital)
- Answer: This is not a steady-state margin; launch-related costs (facilities, manpower, batches) are already being incurred while revenue has not yet scaled. War impact of 1–2% is also temporary. Margin improvement will come sequentially from Q3 with winter-season business and as new products launch; FY27 guidance remains 18.5–20%, and no floor or FY28 target is being provided. (Ashish Adukia, Achin Gupta)
Key Takeaway
Cipla delivered its highest-ever Q1 revenue of ₹7,119 crores, up 2% YoY reported (~4% adjusted for marketing expense reclassification), with One India growing 12% and branded prescriptions +15.4% (IQVIA). EBITDA margin of 16.7% was below steady-state due to product mix, ~1–2% of revenue war-related costs, higher inventory write-offs, and pre-launch U.S. spending, but management retained FY27 margin guidance of 18.5–20%. North America reported US$162 million, with generic Ventolin ramping and four significant launches (3 respiratory including generic Advair, 1 peptide) expected to support a ~US$1 billion annualized exit run rate by Q4 FY27. Yurpeak contributed ~₹80 crores in India and became #2 in the anti-obesity category, while chronic mix reached 60.4%. Risks remain U.S. approval timing, Advair competition, South Africa tender declines, and regulatory follow-ups (Invagen 483, Indore reinspection), alongside the transition to new CFO Dinesh Jain as the company enters a launch-heavy second half.